{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-050805","form_type":"8-K","ticker":"CBIO","cik":"0001253689","company_name":"CRESCENT BIOPHARMA, INC.","filed_at":"2026-07-30T11:36:15+00:00","discovered_at":"2026-07-30T11:40:00.402309+00:00","generated_at":"2026-07-30T11:40:14.958396+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Crescent Biopharma Q2 net loss $24.8M; cash runway extended to H2 2028 after $143.7M offering","bullets":["Net loss $24.8M ($0.74/share) vs $21.8M ($4.93/share) in Q2 2025; R&D expenses rose to $19.4M.","Cash and equivalents $171.6M; pro forma $305.1M after July 2026 public offering of $143.7M gross proceeds.","Enrollment progressing in ASCEND Phase 1/2 for CR-001 (PD-1 x VEGF bispecific); proof-of-concept data expected Q1 2027.","CR-002 (PD-L1 ADC) IND submission mid-2026; global Phase 1/2 trial on track for H2 2026 with data H2 2027.","CR-003 (ITGB6 ADC) Phase 1/2 ongoing in China; proof-of-concept data expected Q1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-050805","json":"https://secwatch.observer/filing/0001628280-26-050805.json","markdown":"https://secwatch.observer/filing/0001628280-26-050805.md","text":"https://secwatch.observer/filing/0001628280-26-050805.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026050805/0001628280-26-050805-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1253689/000162828026050805/cbio-20260730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T11:40:14.958396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}